Drugs / IBI129
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05991349 | Mar → Nov 2024 | neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05991349 ↗ |